AI precision medicine · genomic data OS
Tempus AI
An AI precision-medicine company that uses oncology genetic testing as a data-acquisition funnel to build one of the world's largest multimodal medical datasets and sells that data back to pharma. Of 2025 revenue of $1.27B (+83%), Diagnostics (genetic testing) is 75% ($955M) and funds the model, while Data & Apps at 25% ($316M) is the high-margin leg — it buys Illumina sequencing and NVIDIA compute to create data and sell it to pharma. The re-rating axis is whether data-to-pharma monetization (e.g., the $200M oncology foundation model with AstraZeneca and Pathos) scales faster than the capital-intensive diagnostics leg.
TEM Updated Jul 12, 2026 4 AI consumers· 3 recurring
Per the valuechain.wiki graph, Tempus AI is directly linked to 2 companies (2 supply, 0 revenue relationships) and reaches 3 companies within two hops; the links are backed by 3 dated sources, 1 of them primary filings (as of 2026-07-12).
Financials & Segments
- Total revenue · 2025 revenue $1.27B (+83%)
- Customer concentration · AstraZeneca/Pathos $200M; diagnostics $955M.
- Segments · Diagnostics 75% · Data & Apps 25%
Revenue from
- Hospitals · diagnostics (oncology genetic testing) High confidence
Oncology DNA/RNA and liquid-biopsy testing to hospitals (75% of revenue). - Pharma (AZ · Pathos data · foundation models) High confidence
Data licensing and foundation-model fees ($200M) to pharma like AstraZeneca and Pathos.Confirms EN Yahoo Finance Published Jan 1, 2026: Tempus diagnostics and data arms drive growth (AZ foundation model)
Pays to
- Illumina Medium confidence
Depends on Illumina and others for sequencing, the starting cost of genetic testing — the key upstream input that powers the diagnostics data-funnel (75% of revenue), so sequencing unit cost drives the segment's margin. - NVIDIA Medium confidence
Depends on NVIDIA for the compute to train foundation models — the upstream cost of building the 'model' it sells to pharma, where compute spend scales with the growing dataset.Confirms EN Yahoo Finance Published Jan 1, 2026: Tempus diagnostics and data arms drive growth (AZ foundation model) - Cloud · labs (undisclosed) Low confidence
Cloud and lab operations.
Value-chain ripple (2 tiers)
Following node-to-node links up to 2 tiers; each firm is shown once, at its nearest tier.
| Company | Chain | '21 | '22 | '23 | '24 | '25 | YTD |
|---|---|---|---|---|---|---|---|
| Tempus AI | node | · | · | · | · | +74.9 | +9.4 |
| Illumina | benef1 | +2.8 | -46.9 | -31.1 | -1.3 | -1.8 | +66.4 |
| NVIDIA | benef2 | +125.5 | -50.3 | +239 | +171.2 | +38.9 | +23.7 |
| Amazon | benef2 | +2.4 | -49.6 | +80.9 | +44.4 | +5.2 | +12 |
YTD as of 2026-09-04 · source: Yahoo Finance
Tempus AI operates across AI precision medicine, genomic data OS. It is +9.4% in 2026. The supply side (avg +45.1%) leads the stock (+9.4%), with spending rippling down to suppliers first. Among connected nodes the furthest ahead is Illumina (+66.4%) and the furthest behind is NVIDIA (+23.7%). If chain logic explains the gap, the laggard is the next propagation candidate; if not, the link itself deserves a second look. The re-rating axis is whether data-to-pharma monetization (e.g., the $200M oncology foundation model with AstraZeneca and Pathos) scales faster than the capital-intensive diagnostics leg.
Analysis generated from returns as of 2026-09-04Analyst ratings
Consensus: Buy 2 · Hold 1 · Sell 0 · Avg. target $70 · Price $64.62 (09-04) · Upside +8%
Analyses covering this node
- The application is still a story, the infrastructure demand is already measured: techbio as the first case Jun 23, 2026